EU Approval of Wegovy Pill: A Step Forward, Not a Game-Changer

What happened

Novo Nordisk received EU approval for the first GLP-1 obesity tablet, expanding Wegovy's reach beyond the US. While the approval opens a new revenue stream in Europe, the broader competitive story remains unchanged: Novo faces intensifying price pressure from Lilly's Foundayo and rising rebates. The oral pill has shown strong uptake, with over 200,000 weekly US prescriptions and >80% new-to-GLP-1 patients, but Q1 2026 sales fell 4% at CER due to lower realized prices. Management still guides 2026 adjusted sales down 4-12% at CER, and the stock trades at 12x P/E, reflecting skepticism that volume growth will protect earnings. The EU approval is a positive step for international diversification, but it does not alter the central dilemma: can Novo convert oral volume into sustainable profit margins?

Implication

Investors should remain patient and wait for Q2-Q3 2026 data showing sustained oral prescription growth after Lilly's campaign and stable pricing commentary. The EU approval is a positive catalyst but not a game-changer; the stock's attractive entry is around $45, and the current price of $50.6 offers limited upside until the economics improve. Any position should be sized conservatively given the risk of further price compression.

Thesis delta

The EU approval of Wegovy pill reduces regulatory uncertainty for ex-US expansion but does not alter the core thesis that price pressure outweighs volume growth. The report's WAIT rating is reaffirmed; the key catalysts remain Q2-Q3 prescription trends and pricing stability, not regulatory milestones. The stock's risk/reward is balanced, leaning cautious until earnings protection is visible.